These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35379762)

  • 21. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
    Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
    Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis.
    Cawley N; Tur C; Prados F; Plantone D; Kearney H; Abdel-Aziz K; Ourselin S; Wheeler-Kingshott CAG; Miller DH; Thompson AJ; Ciccarelli O
    Mult Scler; 2018 Jun; 24(7):932-941. PubMed ID: 28516804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
    Cree BA; Arnold DL; Fox RJ; Gold R; Vermersch P; Benedict RH; Bar-Or A; Piani-Meier D; Rouyrre N; Ritter S; Kilaru A; Karlsson G; Giovannoni G; Kappos L
    Mult Scler; 2022 Sep; 28(10):1591-1605. PubMed ID: 35380078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
    Benedict RHB; Tomic D; Cree BA; Fox R; Giovannoni G; Bar-Or A; Gold R; Vermersch P; Pohlmann H; Wright I; Karlsson G; Dahlke F; Wolf C; Kappos L
    Neurology; 2021 Jan; 96(3):e376-e386. PubMed ID: 33328324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK.
    Montgomery S; Woodhouse F; Vudumula U; Gudala K; Duddy M; Kroes M
    J Med Econ; 2022; 25(1):669-678. PubMed ID: 35575251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes.
    Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Siponimod: a new view at the therapy of secondary progressive multiple sclerosis].
    Krasnov VS; Kolontareva YM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7):124-129. PubMed ID: 34460168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Disease-modifying treatment of secondary progressive multiple sclerosis].
    Hoffmann O; Gold R
    Nervenarzt; 2021 Oct; 92(10):1052-1060. PubMed ID: 33656569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis.
    Abdelhak A; Antweiler K; Kowarik MC; Senel M; Havla J; Zettl UK; Kleiter I; Hoshi MM; Skripuletz T; Haarmann A; Stahmann A; Huss A; Gingele S; Krumbholz M; Selge C; Friede T; Ludolph AC; Overell J; Koendgen H; Clinch S; Wang Q; Ziemann U; Hauser SL; Kümpfel T; Green AJ; Tumani H
    Mult Scler Relat Disord; 2024 Jan; 81():105139. PubMed ID: 38000130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients.
    Ferraro D; Guicciardi C; De Biasi S; Pinti M; Bedin R; Camera V; Vitetta F; Nasi M; Meletti S; Sola P
    Acta Neurol Scand; 2020 Jan; 141(1):16-21. PubMed ID: 31350854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis.
    Camara-Lemarroy C; Silva C; Gohill J; Yong VW; Koch M
    Eur J Neurol; 2023 Jan; 30(1):187-194. PubMed ID: 36214614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.
    Naegelin Y; Naegelin P; von Felten S; Lorscheider J; Sonder J; Uitdehaag BMJ; Scotti B; Zecca C; Gobbi C; Kappos L; Derfuss T
    JAMA Neurol; 2019 Mar; 76(3):274-281. PubMed ID: 30615019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland.
    Schur N; Gudala K; Vudumula U; Vadapalle S; Bhadhuri A; Casanova A; Adlard N; Schwenkglenks M
    Pharmacoeconomics; 2021 May; 39(5):563-577. PubMed ID: 33791945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis.
    Lukas C; Knol DL; Sombekke MH; Bellenberg B; Hahn HK; Popescu V; Weier K; Radue EW; Gass A; Kappos L; Naegelin Y; Uitdehaag BM; Geurts JJ; Barkhof F; Vrenken H
    J Neurol Neurosurg Psychiatry; 2015 Apr; 86(4):410-8. PubMed ID: 24973341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis.
    Ladakis DC; Reyes-Mantilla MI; Gadani SP; Mace JW; Dominguez-Penuela SC; Appiah MJ; Smith MD; Bhargava P; Fox RJ; Saidha S; Calabresi PA
    Mult Scler; 2024 Jan; 30(1):35-43. PubMed ID: 37982154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials.
    Orbach R; Zhao Z; Wang YC; O'Neill G; Cadavid D
    PLoS One; 2012; 7(10):e45409. PubMed ID: 23049678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preferential spinal cord volume loss in primary progressive multiple sclerosis.
    Tsagkas C; Magon S; Gaetano L; Pezold S; Naegelin Y; Amann M; Stippich C; Cattin P; Wuerfel J; Bieri O; Sprenger T; Kappos L; Parmar K
    Mult Scler; 2019 Jun; 25(7):947-957. PubMed ID: 29781383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.
    Lizak N; Malpas CB; Sharmin S; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Lugaresi A; Duquette P; Girard M; Prat A; Larochelle C; Trojano M; Grand'Maison F; Grammond P; Sola P; Ferraro D; Hupperts R; Bergamaschi R; Boz C; Van Pesch V; Spitaleri D; Terzi M; Kalincik T;
    JAMA Neurol; 2020 Nov; 77(11):1398-1407. PubMed ID: 32716480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.